Joseph Emmerich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph Emmerich has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Jean-Luc Reny
2 shared publicationsA Hillarp
1 shared publicationAlessandra Bura
1 shared publicationAndreas Hillarp
1 shared publication- Anne-Marie Fischer
Faculté de Médecine, Université Paris-Descartes, INSERM U428, Paris, France
1 shared publication Chantal Lefèbvre
1 shared publication
Latest Publications
- 1 October 2007
- Vol. 98 (4) , 733-7
A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies.
Polymorphic variants of genes encoding blood coagulation proteins have been extensively studied as risk factors for venous or arterial thrombosis A variation in the 3' untranslated region (UTR) involved in the post-transcriptional regulation of factor VII (FVII) gene has been recently identified, a two adenine insertion/deletion at nucleotide 11293. In this study, we investigated its effect on the risk of thrombosis in the frame of two case-control studies, including patients suffering from peripheral arterial disease (PAD) or venous thromboembolic (VTE) disease. The 3'UTR FVII gene polymorphism was investigated i) in 181 patients who had symptomatic atherosclerotic disease of the lower limbs, ii) in 178 patients who had had at least one episode of objectively diagnosed deep venous thrombosis and iii) in controls matched for age and sex. Plasma FVII antigen (FVII: Ag) levels were lower in the presence of the 3'UTR 2A insertion (68.4 +/- 12.3%, 81.3 +/- 14.5% and 89.5 +/- 13.7% in 2A/2A, 2A/0 and 0/0 subjects respectively, p < 0.0001). No significant relationship was found with VTE disease. In the contrary we observed a lower risk of PAD for the 2A/2A compared to the 0/0 genotype after adjustment for traditional risk factors (hypercholesterolemia, smoking status, diabetes and hypertension), with an OR of 0.24 [95% CI 0.06-0.99]. In conclusion, the 2 adenine insertion in the 3'UTR of FVII gene, related to lower plasma FVII levels, is a genetic variation that may contribute to reduce the risk of PAD.
- 1 October 2007
- Vol. 98 (4) , 733-7
A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies.
Polymorphic variants of genes encoding blood coagulation proteins have been extensively studied as risk factors for venous or arterial thrombosis A variation in the 3' untranslated region (UTR) involved in the post-transcriptional regulation of factor VII (FVII) gene has been recently identified, a two adenine insertion/deletion at nucleotide 11293. In this study, we investigated its effect on the risk of thrombosis in the frame of two case-control studies, including patients suffering from peripheral arterial disease (PAD) or venous thromboembolic (VTE) disease. The 3'UTR FVII gene polymorphism was investigated i) in 181 patients who had symptomatic atherosclerotic disease of the lower limbs, ii) in 178 patients who had had at least one episode of objectively diagnosed deep venous thrombosis and iii) in controls matched for age and sex. Plasma FVII antigen (FVII: Ag) levels were lower in the presence of the 3'UTR 2A insertion (68.4 +/- 12.3%, 81.3 +/- 14.5% and 89.5 +/- 13.7% in 2A/2A, 2A/0 and 0/0 subjects respectively, p < 0.0001). No significant relationship was found with VTE disease. In the contrary we observed a lower risk of PAD for the 2A/2A compared to the 0/0 genotype after adjustment for traditional risk factors (hypercholesterolemia, smoking status, diabetes and hypertension), with an OR of 0.24 [95% CI 0.06-0.99]. In conclusion, the 2 adenine insertion in the 3'UTR of FVII gene, related to lower plasma FVII levels, is a genetic variation that may contribute to reduce the risk of PAD.
- 15 August 2004
- Published by EDP Sciences in médecine/sciences
- Vol. 20 (8-9) , 727-729
Thérapie cellulaire de l’ischémie des membres inférieurs
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
- 15 August 2004
- Published by EDP Sciences in médecine/sciences
- Vol. 20 (8-9) , 727-729
Thérapie cellulaire de l’ischémie des membres inférieurs
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
- 19 March 2004
- Vol. 154, 345-53
[Thrombophilia and pregnancy: which tests for which patients? The clinician's point of view].
Venous thromboembolism is the leading cause of death in the ante-partum and post-partum period. The role of genetic thrombophilia in venous thrombosis has been analyzed in several studies, but the role of genetic thrombophilia in fetal loss, intra-uterine growth restriction and pre-eclampsia is much more controversial. While we can give some recommendations on thromboprophylaxis of venous thromboembolism, data concerning the usefulness of antithrombotic treatment in obstetric complications of genetic thrombophilia are lacking. When a laboratory work-up of thrombophilia is required, all the known causes of thrombophilia must be checked as none of them is specific of a single clinical feature, but also because they can be associated in the same patient.
- 19 March 2004
- Vol. 154, 345-53
[Thrombophilia and pregnancy: which tests for which patients? The clinician's point of view].
Venous thromboembolism is the leading cause of death in the ante-partum and post-partum period. The role of genetic thrombophilia in venous thrombosis has been analyzed in several studies, but the role of genetic thrombophilia in fetal loss, intra-uterine growth restriction and pre-eclampsia is much more controversial. While we can give some recommendations on thromboprophylaxis of venous thromboembolism, data concerning the usefulness of antithrombotic treatment in obstetric complications of genetic thrombophilia are lacking. When a laboratory work-up of thrombophilia is required, all the known causes of thrombophilia must be checked as none of them is specific of a single clinical feature, but also because they can be associated in the same patient.
- 1 March 2003
- Vol. 154 (2) , 85-90
Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literature.
Takayasu's arteritis and Crohn's colitis are exceptionally associated and characteristics of patients affected with both diseases have not been fully described. In a group of 44 consecutive Takayasu patients, 4 also had Crohn's disease. This 9% prevalence (95% confidence interval=2.5-21.7%) of Crohn's disease in the group is significantly greater than the highest reported prevalence of the disease in the general population. In these 4 patients, fulfilling 5 or more ACR criteria for Takayasu's disease, Crohn's disease was confirmed with colonoscopic examination and biopsies. Takayasu-Crohn patients were younger at diagnosis and tended to have systemic symptoms more frequently. Other clinical, radiological and biological characteristics were not different between the 2 groups. In the literature, 16 cases of this unusual association have been reported. The diagnosis of Takayasu's disease was simultaneous or posterior to Crohn's disease in 87%. Data on vascular lesions was available in 6 out of 16 patients and in the 4 patients of the present study: the distribution of vascular lesions in Takayasu-Crohn patients did not appear to be different from Takayasu patients. Our results and previous reports suggest that this association of rare diseases is not fortuitous. With respect to the indolent course of Takayasu's arteritis, early diagnosis of vascular lesions in Crohn patients is encouraged.
- 1 March 2003
- Vol. 154 (2) , 85-90
Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literature.
Takayasu's arteritis and Crohn's colitis are exceptionally associated and characteristics of patients affected with both diseases have not been fully described. In a group of 44 consecutive Takayasu patients, 4 also had Crohn's disease. This 9% prevalence (95% confidence interval=2.5-21.7%) of Crohn's disease in the group is significantly greater than the highest reported prevalence of the disease in the general population. In these 4 patients, fulfilling 5 or more ACR criteria for Takayasu's disease, Crohn's disease was confirmed with colonoscopic examination and biopsies. Takayasu-Crohn patients were younger at diagnosis and tended to have systemic symptoms more frequently. Other clinical, radiological and biological characteristics were not different between the 2 groups. In the literature, 16 cases of this unusual association have been reported. The diagnosis of Takayasu's disease was simultaneous or posterior to Crohn's disease in 87%. Data on vascular lesions was available in 6 out of 16 patients and in the 4 patients of the present study: the distribution of vascular lesions in Takayasu-Crohn patients did not appear to be different from Takayasu patients. Our results and previous reports suggest that this association of rare diseases is not fortuitous. With respect to the indolent course of Takayasu's arteritis, early diagnosis of vascular lesions in Crohn patients is encouraged.
- 1 January 2003
- Vol. 53 (1) , 14-9
[Frequency and risk factors of thrombo-embolic venous disease].
Thromboembolic disease is a frequent pathology, responsible of around 10,000 deaths each year, in France. Post-thrombotic syndrome is also a health policy problem. Acquired and genetic causes of venous thrombo-embolism are better understood and have demonstrated that it is a multifactorial disease. The combination of several environmental and/or genetic risk factors and their understanding in the risk of the disease is important for prophylaxis and treatment after a first episode of the disease. Association between cancer and venous thromboembolism has been recently studied, and is most often associated with a bad prognosis of the underlying cancer.
- 1 January 2003
- Vol. 53 (1) , 14-9
[Frequency and risk factors of thrombo-embolic venous disease].
Thromboembolic disease is a frequent pathology, responsible of around 10,000 deaths each year, in France. Post-thrombotic syndrome is also a health policy problem. Acquired and genetic causes of venous thrombo-embolism are better understood and have demonstrated that it is a multifactorial disease. The combination of several environmental and/or genetic risk factors and their understanding in the risk of the disease is important for prophylaxis and treatment after a first episode of the disease. Association between cancer and venous thromboembolism has been recently studied, and is most often associated with a bad prognosis of the underlying cancer.
- 1 January 2003
- Vol. 187 (1) , 19
[Epidemiology of venous thrombosis].
Venous thrombo-embolic disease (VTE) is a frequent pathology, responsible for around 10,000 deaths each year in France. Post-thrombotic sequellae is also a main problem related to the disease. The epidemiology of acquired and genetic risk factors of VTE is better understood and has allowed to show that in many cases it is a multifactorial disease. The association of several environmental or genetic and their analysis in the physiopathology of the disease and in the risk of recurrency is important in order to allow a better prevention of the disease and of its recurrencies.
- 1 January 2003
- Vol. 187 (1) , 19
[Epidemiology of venous thrombosis].
Venous thrombo-embolic disease (VTE) is a frequent pathology, responsible for around 10,000 deaths each year in France. Post-thrombotic sequellae is also a main problem related to the disease. The epidemiology of acquired and genetic risk factors of VTE is better understood and has allowed to show that in many cases it is a multifactorial disease. The association of several environmental or genetic and their analysis in the physiopathology of the disease and in the risk of recurrency is important in order to allow a better prevention of the disease and of its recurrencies.
- 1 December 2002
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 32 (5-6) , 346-348
Infection and venous thrombosis
Chlamydia pneumoniae infection has been linked to atherosclerosis, but a possible relationship with venous thromboembolism (VTE) had not been sought. We determined circulating anti-C. pneumoniae antibody levels in patients with VTE. Fifty-four percent of the cases and 15.9% of the controls had specific IgG titers of at least 256 (p<0.0001). The crude odds ratio for VTE was 6.2 (95% CI, 3.8-10.1), and rose to 7.7 (4.5-13.2) after excluding subjects carrying the factor V Arg 506 Gln or factor II G 20210 A mutations. Other studies did not confirm such an association or found a lower odds ratio. This association remains to be confirmed in other case-control or prospective studies.
- 1 December 2002
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 32 (5-6) , 346-348
Infection and venous thrombosis
Chlamydia pneumoniae infection has been linked to atherosclerosis, but a possible relationship with venous thromboembolism (VTE) had not been sought. We determined circulating anti-C. pneumoniae antibody levels in patients with VTE. Fifty-four percent of the cases and 15.9% of the controls had specific IgG titers of at least 256 (p<0.0001). The crude odds ratio for VTE was 6.2 (95% CI, 3.8-10.1), and rose to 7.7 (4.5-13.2) after excluding subjects carrying the factor V Arg 506 Gln or factor II G 20210 A mutations. Other studies did not confirm such an association or found a lower odds ratio. This association remains to be confirmed in other case-control or prospective studies.
- 1 September 2001
- Vol. 86 (3) , 809-16
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-1 8.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups.
- 1 September 2001
- Vol. 86 (3) , 809-16
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-1 8.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups.
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (09) , 809-816
Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups. * The study group for pooled-analysis in venous thromboembolism.
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (09) , 809-816
Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups. * The study group for pooled-analysis in venous thromboembolism.
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (12) , 1117-1118
The FXIII Val 34 Leu Mutation and the Risk of Venous Thrombosis
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (12) , 1117-1118
The FXIII Val 34 Leu Mutation and the Risk of Venous Thrombosis